news.cision.com

As of 31 July 2022, net asset value for Esmaeilzadeh Holding AB (publ) (“the Company”) was SEK 7.73 billion, corresponding to a net asset value per share of SEK 10,200. For further information, please contact: Saeid Esmaeilzadeh, CEO and founder +46 707 18 70 61, saeid@ehab.group Nils Fredrik Dehlin, General Counsel & IR +46 720 90 26 99, nilsfredrik@ehab.group The information was submitted for publication, through the agency of the contact person set out above, at 09.00 CEST on 17 August. About Esmaeilzadeh Holding AB (publ) EHAB is an investment company that

Glaston Oyj Abp - Managers' Transactions

Glaston Corporation Stock Exchange Release, Managers' Transactions 17.8.2022 at 10.00 amGlaston Oyj Abp - Managers' Transactions____________________________________________Person subject to the notification requirementName: Veli-Matti ReinikkalaPosition: Member of the Board/Deputy member Issuer: Glaston Oyj AbpLEI: 743700V3I7CLI3DJ8L62Notification type: INITIAL NOTIFICATIONReference number: 18472/7/8____________________________________________ Transaction date: 2022-08-15Venue: NASDAQ HELSINKI LTD (XHEL)Instrument type: SHAREISIN: FI4000369657Nature of the

Advansia awarded assignment with Statsbygg for the Ocean Space Centre in Norway

Advansia, part of AFRY, will join Statsbygg’s project organisation in the development of the Ocean Space Centre in Trondheim, Norway. When completed it will be one of the world’s most advanced facilities for research and education.The Ocean Space Centre will be central for increasing value and reconstructing the marine industries locally, nationally and globally. It will contribute to the green transition of the maritime industry, and secure Norway’s position as a leading maritime nation. As a part of the assignment, Advansia will deliver project management services including supply

Glaston Oyj Abp - Managers' Transactions

Glaston Corporation Stock Exchange Release, Managers' Transactions 17.8.2022 at 10.00 amGlaston Oyj Abp - Managers' Transactions____________________________________________Person subject to the notification requirementName: Arja TalmaPosition: Member of the Board/Deputy member Issuer: Glaston Oyj AbpLEI: 743700V3I7CLI3DJ8L62Notification type: INITIAL NOTIFICATIONReference number: 18478/5/4____________________________________________ Transaction date: 2022-08-15Venue: NASDAQ HELSINKI LTD (XHEL)Instrument type: SHAREISIN: FI4000369657Nature of the transaction:

Glaston Oyj Abp - Managers' Transactions

Glaston Corporation Stock Exchange Release, Managers' Transactions 17.8.2022 at 10.00 amGlaston Oyj Abp - Managers' Transactions____________________________________________Person subject to the notification requirementName: Tero TelarantaPosition: Member of the Board/Deputy member Issuer: Glaston Oyj AbpLEI: 743700V3I7CLI3DJ8L62Notification type: INITIAL NOTIFICATIONReference number: 18486/5/4____________________________________________ Transaction date: 2022-08-15Venue: NASDAQ HELSINKI LTD (XHEL)Instrument type: SHAREISIN: FI4000369657Nature of the

Invitation to presentation of Pagero’s interim report for Q2 2022

Wed, Aug 17, 2022 08:45 CET

Pagero Group AB (publ) publishes interim report for January – June 2022 on 23 August 2022 at 07.30 CET and invites to a presentation of the report at 10.00 CET on the same day.Bengt Nilsson, CEO of Pagero, will present Pagero’s first half year in a webcast. It will be possible to submit questions in writing during the presentation, which will be answered at the end of the broadcast. Follow the presentation live: Link For more informationBengt Nilsson, CEOBengt.nilsson@pagero.com Jan-Olof Ohlsson, CFOJan-olof.ohlsson@

Clean Industry Solutions Holding Europe AB: Quarterly Report April-June 2022

Q2 from 01.04.2022 to 30.06.2022 (01.04.2021 to 30.06.2021), 01-06 from 01.01.2022 to 30.06.2022 (01.01.2021 to 30.06.2021), FY from 01.01.2021 to 31.12.2021 The report can be found here: https://cleanindustrysolutions.com/en/investor-relations/financial-reports/CISH AB 2022 2021 Diff. in 2022 2021 Diff. 2021Group Q2 Q2 % 01-06 01-06 in % FYRESULTS INBRIEF| in TSEKSales 3,283 256 +1.182.6 3,718 381 +876.0

Delårsrapport 1 JANUARI – 30 JUNI 2022 FLOWSCAPE TECHNOLOGY AB (publ), ORG.Nr. 556725-4866

Wed, Aug 17, 2022 08:40 CET

Styrelsen och verkställande direktören för Flowscape Technology AB avger härmed rapport för perioden januari – juni 2022. Belopp anges i tusentals kronor. Siffror inom parentes avser motsvarande period föregående This information is only available in Swedish.Januari – Juni i korthet, concern FÖRSTA HALVÅRET(JANUARI-JUNI) · Nettoomsättningen uppgick till 21 171 (14 960) TSEK · Rörelseresultat före avskrivningar uppgick till 1 498 (61) TSEK · Resultat efter finansiella poster uppgick till -9 342 (-11 834) TSEK · Bokade ordrar uppgick till 14 354 (10 160)[1] TSEK, varav 3

Crunchfish signs agreement with Ximmerse for XR Skeleton Stereo

Crunchfish Gesture Interaction AB ("Crunchfish") signs a commercial license agreement with Guangdong Virtual Reality Technology CO LTD (“Ximmerse”), to provide Ximmerse’s next generation AR-glasses with Crunchfish’s latest hand tracking technologies - XR Skeleton and XR Skeleton Stereo. Ximmerse will integrate Crunchfish’s software in all new models of AR-glasses to enable touchless interaction. It is a 3-years agreement, with a business model that includes an initial fee of $25,000US as well as a running royalty per produced unit that includes Crunchfish’s software.The agreement gives

HC Andersen Capital Events 17/8: Meet the management in NTG, Xplora and BioPorto

HC Andersen Capital is today hosting several digital events where you can meet and ask questions directly to the top management. It is free for all to attend.NTG - Presentation of the Q2 report 2022On 12 August, Nordic Transport Group A/S published an unsurprisingly strong account for the second quarter of 2022. However, the guidance for 2022 is maintained. Thus, NTG realizes an impressive revenue growth in the quarter of 58.7% y/y, of which 25% is organic, which means that the revenue lands at DKK 2,729 million. against the consensus of DKK 2,597 million. Adjusted EBIT is DKK 216.8

Genova Property Group Interim Report January–June 2022

January–June 2022 period · Rental income amounted to SEK 185.7m (141.8), an increase of 31%. · Net operating income amounted to SEK 132.3m (104.2), an increase of 27%. · Income from property management increased 62% to SEK 56.3m (34.8), of which income from property management attributable to shareholders was SEK 31.1m (11.0), corresponding to SEK 0.74 (0.28) per share. · Net income after tax amounted to SEK 342.5m (263.8), corresponding to SEK 7.06 (6.06) per share. · Long-term net asset value attributable to shareholders increased 42% to SEK 3,649.5m (2,563.0),

Nepa strengthens its growth initiatives and appoints Ferry Wolswinkel as Chief Revenue Officer

STOCKHOLM, Sweden – Nepa has in accordance with its growth strategy established a new role and appointed Ferry Wolswinkel as Chief Revenue Officer (CRO) and new member of the Group Management team. He will be responsible for accelerating the company’s growth, including the global sales and marketing organization, developing its revenue streams and optimizing sales growth in select markets and product categories. Ferry has extensive experience from global sales roles in tech and consumer insight companies, most recently as Vice President Sales for the London-based consumer intelligence

Scandion Oncology extends PANTAX trial due to better-than-expected tolerability of SCO-101

Good tolerability allows for continued dose escalation in the dose-finding PANTAX phase 1b-trial with SCO-101 as combination therapy in pancreatic cancer. Consequently, readout from the trial is now expected in the first half of 2023.Scandion Oncology (Scandion), a biotech company developing first-in-class medicines aimed at treating cancer which is resistant to current treatment options, has observed a better-than-expected tolerability of its potential new cancer treatment SCO-101 in the dose-finding PANTAX phase 1b-trial. Thus, dosing is now escalated to higher levels than expected based

ORGANOCLICK AB (PUBL) PUBLISH INTERIM REPORT FOR Q2 2022

Wed, Aug 17, 2022 08:05 CET

The second quarter had a mixed outcome for the Group. Declining sales in the building supplier market negatively affected sales of our consumer products. On the other hand, we doubled the sales of binders in the Nonwoven and technical textile business unit, through increased deliveries to Duni and Ahlstrom-Munksjö. The net meant a reduction in the Group’s sales by -3.3 (10.4) % to SEK 38.5 (39.8) million.Translation from CEO Mårten Hellbergs comments to the Interim Report. Q2, 1 April - 30 June 2022 The Group compared with 2021 » Net revenue amounted to SEK 38.53 (36.06) million

2020 Bulkers Ltd. (2020) - Results for the second quarter and first half of 2022

Oslo, Norway, August 17, 2022 2020 Bulkers Ltd. (“2020 Bulkers” or the “Company”), today announced its unaudited financial and operating results for the three and six months ended June 30, 2022. Key events during the second quarter of 2022 · The Company reported net profit of US$12.0 million and EBITDA of US$17.4 million for the second quarter of 2022. · Achieved average time charter equivalent earnings of approximately US$32,300 per day, gross. · The Company declared total cash distributions of US$0.52 per share for the months of April, May and June 2022. · In

Episurf Medical provides update on process for UK NICE guidelines

Episurf Medical (NASDAQ: EPIS B) today provides an update on the work related to the UK National Institute for Health and Care Excellence’s (NICE) guidelines. NICE guidelines are evidence-based recommendations for health and care in the UK, to help healthcare professionals in their work. The guidelines also support payors and authorities on their decisions to reimburse various procedures and devices. Episurf Medical has participated in several NICE hearings for its Episealer® knee implant family, and the company has been informed about the timetable, which is likely to result in guidelines

Vicore IPF interim data selected as an oral “late-breaker” at the ERS congress

· The AIR trial is a single arm, multicenter phase 2 study in patients with idiopathic pulmonary fibrosis (IPF) · Interim data have shown stabilization of the disease and an increase in lung capacity at 24 and 36 weeks · Oral presentation by Professor Toby Maher on September 4 at 15:00 CET Gothenburg, August 17, 2022 - Vicore Pharma Holding AB (publ) (“Vicore”), a clinical-stage pharmaceutical company developing medicines targeting the angiotensin II type 2 receptor (AT2R), today announces that the previously published interim data from AIR, a phase 2 trial in IPF), will be

Notice of Annual General Meeting in Pomegranate Investment AB

NOT FOR DISTRIBUTION IN THE UNITED STATES OR TO ANY U.S. PERSONThe shareholders in Pomegranate Investment AB (publ) with Reg. No. 556967-7247 and registered office in Stockholm are hereby convened to the annual general meeting to be held on 14 September 2022 at 3 p.m. at the offices of Advokatfirman Vinge, Smålandsgatan 20, SE-111 46 Stockholm. Preconditions for participation Shareholders who wish to participate in the general meeting must be included in the shareholders’ register maintained by Euroclear Sweden AB as of 6 September 2022. Nominee registered shares To

TikoMed Announces Appointment of Two Independent Directors

Viken – 17th August, 2022 – Today, Swedish biopharmaceutical company TikoMed AB announced the appointment of two new members to its Board of Directors, Tara Heitner and Pete Zorn. “We are excited to welcome Tara and Pete to our Board,” said Adam Bruce, Founder and Chairman of the Board of TikoMed. “Tara and Pete are perfect fits for our next steps with their strong track records of transactional experience. They bring years of organizational and business development expertise and leadership that will serve the company well as we aim to grow our business focused on the ILB® drug platform

Inify’s first ultramodern laboratory on track

STOCKHOLM – August 17 2022 – Inify Laboratories, a company providing fully digitalized pathology laboratory services for cancer diagnostics, listed in June 2022 on the Euronext Growth in Oslo, is on track in building its first ultramodern laboratory at Campus Solna, Sweden, next to world-leading healthcare. “We signed a five-year leasing contract for our office and laboratory facilities at Campus Solna. These will be Inify’s headquarters, housing our first laboratory as well as our Center of Excellence,” says CEO Fredrik Palm at Inify. The company expects to move into the new facility

Implema partners with Litorina to accelerate growth - Lars Wollung new chairman of the board

Implema, Sweden’s leading implementation specialist for SAP and Microsoft Dynamics enters a new phase in its growth journey as it partners with private equity company Litorina and announces Lars Wollung as chairman of the board. The partnership will enable Implema to accelerate growth by expanding its service offering, strengthening its position as a long-term digital transformation partner. Litorina is a Swedish private equity firm with extensive experience partnering with innovative companies in the Nordics. With this move, Litorina takes a majority stake in Implema, while Implema’s

Remedy Entertainment Oyj: Managers' Transactions – Kaisa Salakka

Remedy Entertainment Oyj – Managers' Transactions 17 August 2022 9.00 a.m. (EEST) ____________________________________________ Person subject to the notification requirementName: Kaisa SalakkaPosition: Member of the BoardIssuer: Remedy Entertainment OyjLEI: 7437003VZ3JPF7DBTG92Notification type: INITIAL NOTIFICATIONReference number: 18520/4/6 ____________________________________________ Transaction date: 2022-08-16Venue: NASDAQ HELSINKI LTD (XHEL)Instrument type: SHAREISIN: FI4000251897Nature of the transaction: ACQUISITION Transaction details (1):

SmartCraft ASA (SMCRT) - Invitation to presentation of the second quarter 2022 results and deep dive presentation